Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome

Clinical Laboratory

Volumn 51, Issue 3-4, 2005, Pages 117-126

  Silberer, Hannah ^a   Küppers, Bruno ^b   Mickisch, Oliver ^b   Baniewicz, Wojtek ^b   Drescher, Maren ^a   Traber, Lydia ^c   Kempf, Alexander ^c   Schmidt Gayk, Heinrich ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Gastroenterology Group Practice   (Germany)

^c Limbach Laboratory   (Germany)

Author keywords

Calprotectin; Inflammatory bowel disease; Irritable bowel syndrome; Lactoferrin; Leukocyte proteins; Lysozyme; Myeloperoxidase; PMN elastase

Indexed keywords

CALPROTECTIN; LACTOFERRIN; LEUKOCYTE ELASTASE; LYSOZYME; MYELOPEROXIDASE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENTERITIS; FECES ANALYSIS; FECES LEVEL; FEMALE; HUMAN; IMMUNOASSAY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN STABILITY; REVIEW; ROC CURVE; SUPERNATANT; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LACTOFERRIN; LEUKOCYTE ELASTASE; LEUKOCYTE L1 ANTIGEN COMPLEX; LEUKOCYTES; MALE; MIDDLE AGED; MURAMIDASE; PEROXIDASE; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 17144363641     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Arndt B, Schmidt-Gayk H, Schürmann G, Betzler M, Herfarth C. Fäkale Parameter zur Beurteilung der Krankheitsaktivität bei Morbus Crohn. Klin Lab 1993;39:867-76.
2. Gao P, John MR, Schmidt-Gayk H, Arndt B, Scheida M, Theuer D. Solid-phase competitive luminescence immunoassay for lysozyme in faeces. Clin Chim Acta 1995;239:167-77.
3. Schoof E, John MR, Arndt B, Gao P, Theuer D, Sieg A, Schmidt-Gayk H. Solid phase competitive luminescence immunoassay for immunoglobulin A in faeces: development and clinical validation. Clin Chim Acta 1997;261:1-17.
4. Sieg A, Thoms Ch, Lüthgens K, John MR, Schmidt-Gayk H. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int J Colorectal Dis 1999; 14:267-71.
5. Poullis A, Foster R, Northfield TC, Mendal MA. Faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:675-681
6. Tibble J, Teanhon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fangerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
7. Tibble J, Sigthorsson G, Bridger S, Fangerhol M, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol 2000;119:15-22.
8. Bunn SK, Bisset WM, Main MJC, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation of a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Ped Gastroenterol Nutr 2001;33:14-22.
9. Bjarnason I, Sherwood R. Fecal calprotectin: a significant step in the noninvasive assessment of intestinal inflammation. J Pediatr Gastroenterol Nutrition 2001;33:11-3.
10. Adeyemi EO, Hodgson HJF. Lactoferrin: a correlate of disease activity in inflammatory bowel disease. Europ J Gastroenterol Hepatol 1991;3:51-6.
11. Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259-64.
12. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastoenterol 1996;91:927-34.
13. Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002;97:360-9.
14. Dick W, Braun O, Nagel W. Lysozym bei Kindern mit akuten und chronisch entzündlichen Darmerkrankungen. Pädiatrie Pädologie 1985;20:143-50.
15. Costongs GMPJ, Hemrika MH, Engels LGJB, Bos LP, Bas BM, Flendrig JA, Janson PCW. Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal disease. Clin Chim Acta 1987;167:125-34.
16. Brouwer J, Smekens F. Instability of fecal lysozyme. Clin Chim Acta 1991;201;137-8.
17. Dwarakanath AD, Finnie IA, Beesley CM, O'Dowd GM, Nash J, Tsai HH, Parker N, Rhodes JM. Differential excretion of leukocyte granule components in inflammatory bowel disease: implications for pathogenesis. Clin Sci 1997;92:307-13.
18. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998; 45:69-73.
19. Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, Schölmerich J. PMN-Elastase in assessment of patients with inflammatory bowel disease. Digestive Dis Sci 1993;38:1638-44.
20. Heinichen C, Buessecker F, Arndt B, Schmidt-Gayk H, Kramer M. PMN-Elastase in Faeces: Etablierung eines Lumineszenz-Immunoassays und Prüfung der diagnostischen Relevanz bei Morbus Crohn. Clin Lab 1995;41:539-45.
21. Saitoh O, Sugi K, Matsuse R, Uchida K, Matsumoto H, Nakagawa K, Takada K, Yoshizumi M, Hirata I, Katsu K. The forms and the levels of fecal PMN-elastase in patients with colorectal diseases. Am J Gastroenterol 1995;90:388-93.
22. Stange EF, Riemann J, von Herbay A, Lochs H, Fleig WE, Schölmerich J, Kruis W, Porschen R, Bruch H-P, Zeitz M, Schreiber S, Moser G, Matthes H, Selbmann HK, Goebell H, Caspary WF. Diagnostics and treatment of ulcerative colitis - Results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 2001;39:19-20 (German language)
23. Stange EF, Schreiber S, Fölsch UR, von Herbay A, Schölmerich J, Hoffmann J, Zeitz M, Fleig WE, Buhr HJ, Kroesen AJ, Moser G, Matthes H, Adler G, Reinshagen M, Stein J. Diagnostics and treatment of Crohn's disease - Results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 2003;41:19-20 (German language)
24. Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther 1996;10:321-326.
25. Lüthgens K, Maier A, Kampert I, Sieg A, Schmidt-Gayk H. Hemoglobin-haptoglobin-complex: a highly sensitive assay for the detection of fecal occult blood. Clin Lab 1998;44:543-51.
26. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodic study. Scand J Gastroenterol 1992;27:793-8.